Oncology is the leading therapeutic area. This dominance is driven by the proliferation of immunotherapies, targeted therapies, and biomarker-driven protocols which require specialized infrastructure, integrated diagnostics, and the ability to manage complex inclusion criteria.
Key growth drivers include the increasing complexity of clinical protocols in oncology and cardiology, the globalization of clinical development to access diverse patient populations, the rapid adoption of digital tools like AI and eSource, and a surge in strategic M&A activities to consolidate fragmented site infrastructures.
AI is being used to power predictive algorithms and screening platforms that identify eligible participants more quickly and accurately. For example, PPD (part of Thermo Fisher Scientific) launched an AI-powered platform in 2023 to accelerate recruitment for cardiology and rare disease studies.
The Asia-Pacific (APAC) region is the fastest-growing market. Growth is fueled by large treatment-naïve populations, cost-effective operations, fast ethical approvals, and significant infrastructure investments in countries like China, India, and South Korea.
The services segment dominates because sponsors increasingly rely on third-party site networks for end-to-end solutions, including feasibility planning, patient enrollment, regulatory reporting, and data management. These networks help minimize operational bottlenecks and reduce trial cycle times.
Sites are evolving to become more patient-centric by offering flexible visit schedules, telemedicine, concierge services, and wearable integration. These enhancements improve patient enrollment and retention, particularly for rare disease and oncology cohorts that require personalized approaches.
Phase II trials are seeing a peak in demand as sponsors push for efficacy validation across diverse cohorts. Investigative site networks provide the necessary scalability and agility to execute these protocols consistently across multiple sites, increasing the reliability of data for regulatory submissions.
The market faces several hurdles, including regulatory variations across different geographies, high operational costs associated with network expansion, a shortage of trained personnel in developing markets, and complexities regarding data privacy in digital trial ecosystems.
The market features prominent players such as ICON plc, IQVIA, PPD (Thermo Fisher Scientific), Syneos Health, Parexel International, Clinedge, FOMAT Medical Research, Accell Clinical Research, Velocity Clinical Research, and MedPharmics.
